Payment overview · 2025
General Payments
$306.45
16 reported records · 11 companies
Healthcare provider profile · identity verified
Tara Roa, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HAYS, KS · NPI 1043286933
Verified facts
What the public records show
CMS Open Payments records show Tara Roa, PA received $306.45 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.80 | 15.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.62 | 11.0% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.28 | 10.5% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $30.82 | 10.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.69 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.66 | 9.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.20 | 8.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.37 | 6.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.90 | 6.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.68 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.43 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.45 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $30.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 160 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 174 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
174 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 56 |
| Ozempic | Semaglutide | 181 | 29 |
| Mounjaro | Tirzepatide | 174 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 168 | 46 |
| Jardiance | Empagliflozin | 160 | 31 |
| Gabapentin | Gabapentin | 142 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 38 |
| Tresiba Flextouch U-200 | Insulin Degludec | 136 | 28 |
| Metformin Hcl Er | Metformin Hcl | 134 | 31 |
| Losartan Potassium | Losartan Potassium | 133 | 44 |
| Metformin Hcl | Metformin Hcl | 126 | 39 |
| Eliquis | Apixaban | 122 | 18 |
| Novolog Flexpen | Insulin Aspart | 118 | 24 |
| Tramadol Hcl | Tramadol Hcl | 115 | 33 |
| Montelukast Sodium | Montelukast Sodium | 114 | 26 |
| Simvastatin | Simvastatin | 99 | 33 |
| Lisinopril | Lisinopril | 94 | 25 |
| Omeprazole | Omeprazole | 93 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 14 |
| Furosemide | Furosemide | 77 | 20 |
| Lorazepam | Lorazepam | 76 | 17 |
| Glipizide Er | Glipizide | 73 | 20 |
| Warfarin Sodium | Warfarin Sodium | 69 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 66 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 21 |
| Carvedilol | Carvedilol | 62 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 21 |
| Mirtazapine | Mirtazapine | 57 | 13 |
| Potassium Chloride | Potassium Chloride | 55 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 16 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 11 |
| Clonazepam | Clonazepam | 50 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 11 |
| Allopurinol | Allopurinol | 48 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Novolog | Insulin Aspart | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 14 |
| Trazodone Hcl | Trazodone Hcl | 40 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Gemtesa | Vibegron | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Meloxicam | Meloxicam | 24 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Valsartan | Valsartan | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Tresiba | Insulin Degludec | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.45 · 16 records | Amgen Inc. | AREXVY, CeQur Simplicity, EVENITY, GEMTESA, GIVLAARI, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Omnipod, REPATHA, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error